Orphan drug accelerator has now raised $26m from investors including Lundbeckfond Ventures and Pfizer, to help create companies focused on rare diseases.
Cydan, a US-based orphan drug accelerator, has expanded its initial round of financing by $10m, led by new investors Lundbeckfond Ventures, an evergreen life science venture fund owned by the Denmark-based healthcare holding company Lundbeck Foundation, and life sciences venture capital investor Bay City Capital; they were joined by Cydan’s previous investors, venture capital firm New Enterprise Associates (NEA) and life sciences real estate investor Alexandria Venture Investments.
The expansion brings Cydan’s total financing raised to $26 million. Cydan launched…
